1. Home
  2. BEAM vs CENX Comparison

BEAM vs CENX Comparison

Compare BEAM & CENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$26.68

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Century Aluminum Company

CENX

Century Aluminum Company

HOLD

Current Price

$32.03

Market Cap

2.7B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
CENX
Founded
2017
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Aluminum
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.7B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
BEAM
CENX
Price
$26.68
$32.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
3
Target Price
$48.09
$33.00
AVG Volume (30 Days)
2.0M
1.9M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.83
Revenue
$55,701,000.00
$2,525,100,000.00
Revenue This Year
N/A
$16.07
Revenue Next Year
$26.52
N/A
P/E Ratio
N/A
$37.84
Revenue Growth
N/A
20.15
52 Week Low
$13.53
$13.05
52 Week High
$35.25
$34.52

Technical Indicators

Market Signals
Indicator
BEAM
CENX
Relative Strength Index (RSI) 55.81 60.12
Support Level $25.86 $31.17
Resistance Level $28.10 $33.06
Average True Range (ATR) 1.56 1.23
MACD 0.17 0.26
Stochastic Oscillator 57.39 81.14

Price Performance

Historical Comparison
BEAM
CENX

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About CENX Century Aluminum Company

Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.

Share on Social Networks: